Integrated boost IMRT with FET-PET-adapted local dose escalation in glioblastomas: Results of a prospective phase II study

Strahlentherapie und Onkologie

Volumn 188, Issue 4, 2012, Pages 334-339

  Piroth, M D ^a,b   Pinkawa, M ^a,b   Holy, R ^a,b   Klotz, J ^a,b   Schaar, S ^a,b   Stoffels, G ^b   Galldiks, N ^b,c   Coenen, H H ^b   Kaiser, H J ^a   Langen, K J ^b   Eble, M J ^a,b  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b FORSCHUNGSZENTRUM JÜLICH   (Germany)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Dose escalation; Dose fractionation; Glioblastoma; Radiotherapy

Indexed keywords

2 FLUOROETHYL LEVO TYROSINE F 18; BEVACIZUMAB; CARMUSTINE; TEMOZOLOMIDE; TYROSINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHEMORADIOTHERAPY; CLINICAL ARTICLE; COGNITION; DISEASE FREE SURVIVAL; DRUG DOSE ESCALATION; FEMALE; FOLLOW UP; GLIOBLASTOMA; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; QUALITY OF LIFE; RADIATION DOSE; TUMOR GROWTH;

ADULT; AGED; BRAIN; CHEMORADIOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; QUALITY OF LIFE; RADIATION INJURIES; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, INTENSITY-MODULATED; SUPRATENTORIAL NEOPLASMS; TYROSINE;

EID: 84862706167     PISSN: 01797158     EISSN: 1439099X     Source Type: Journal    
DOI: 10.1007/s00066-011-0060-5     Document Type: Article

References (32)

1. Balducci M, Apicella G, Manfrida S et al (2010) Single-arm phase II study of conformal radiation therapy and temozolomide plus fractionated stereotactic conformal boost in high-grade gliomas: final report. Strahlenther Onkol 186:558-564
2. Baumert BG, Lutterbach J, Bernays R et al (2003) Fractionated stereotactic radiotherapy boost after post-operative radiotherapy in patients with high-grade gliomas. Radiother Oncol 67:183-190 (Pubitemid 36700461)
3. Blonigen BJ, Steinmetz RD, Levin L et al (2010) Irradiated volume as a predictor of brain radionecrosis after linear accelerator stereotactic radiosurgery. Int J Radiat Oncol Biol Phys 77:996-1001
4. Cardinale R, Won M, Choucair A et al (2006) A phase II trial of accelerated radiotherapy using weekly stereotactic conformal boost for supratentorial glioblastoma multiforme: RTOG 0023. Int J Radiat Oncol Biol Phys 65:1422-1428 (Pubitemid 44425201)
5. Chan JL, Lee SW, Fraass BA et al (2002) Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy. J Clin Oncol 20:1635-1642 (Pubitemid 34260545)
6. Fowler JF (1989) The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol 62:679-694
7. Gerstein J, Franz K, Steinbach JP et al (2011) Radiochemotherapy with temozolomide for patients with glioblastoma: prognostic factors and long-term outcome of unselected patients from a single institution. Strahlenther Onkol 187:722-728
8. Grosu AL, Weber WA, Franz M et al (2005) Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys 63:511-519 (Pubitemid 41317169)
9. Guckenberger M, Mayer M, Buttmann M et al (2011) Prolonged survival when temozolomide is added to accelerated radiotherapy for glioblastoma multiforme. Strahlenther Onkol 187:548-554
10. Hamacher K, Coenen HH (2002) Efficient routine production of the 18F-labelled amino acid O-2-18F fluoroethyl-L-tyrosine. Appl Radiat Isot 57:853-856 (Pubitemid 35284220)
11. Langen KJ, Hamacher K, Weckesser M et al (2006) O-(2-[18F]fluoroethyl)-L- tyrosine: uptake mechanisms and clinical applications. Nucl Med Biol 33:287-294
12. Lee SW, Fraass BA, Marsh LH et al (1999) Patterns of failure following high-dose 3-D conformal radiotherapy for high-grade astrocytomas: a quantitative dosimetric study. Int J Radiat Oncol Biol Phys 43:79-88 (Pubitemid 29065835)
13. Macdonald DR, Cascino TL, Schold SC Jr et al (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280 (Pubitemid 20195640)
14. Milano MT, Okunieff P, Donatello RS et al (2010) Patterns and timing of recurrence after temozolomide- based chemoradiation for glioblastoma. Int J Radiat Oncol Biol Phys 78:1147-1155
15. Oppitz U, Maessen D, Zunterer H et al (1999) 3D-recurrence-patterns of glioblastomas after CT-planned postoperative irradiation. Radiother Oncol 53:53-57
16. Pauleit D, Floeth F, Hamacher K et al (2005) O-(2-[18F]fluoroethyl)-L- tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain 128:678-687 (Pubitemid 40380202)
17. Piroth MD, Pinkawa M, Holy R et al (2009) Integrated- boost IMRT or 3-D-CRT using FET-PET based auto-contoured target volume delineation for glioblastoma multiforme - a dosimetric comparison. Radiat Oncol 4:57
18. Piroth MD, Pinkawa M, Holy R et al (2011) Prognostic value of early 18F-fluoroethylthyrosine PET after radiochemotherapy in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 80:176-184
19. Piroth MD, Holy R, Pinkawa M et al (2011) Prognostic impact of postoperative, pre-irradiation 18F-fluoroethyl-L-tyrosine uptake in glioblastoma patients treated with radiochemotherapy. Radiother Oncol 99:218-224
20. Rickhey M, Koelbl O, Eilles C et al (2008) A biologically adapted dose-escalation approach, demonstrated for 18F-FET-PET in brain tumors. Strahlenther Onkol 184:536-542
21. Rickhey M, Moravek Z, Eilles C et al (2010) 18F-FET-PET-based dose painting by numbers with protons. Strahlenther Onkol 186:320-326
22. Roesch P, Netsch T, McNutt T et al (2003) Syntegra - automated image registration algorithms. Philips White Paper
23. Shrieve DC, Alexander E III, Black PM et al (1999) Treatment of patients with primary glioblastoma multiforme with standard postoperative radiotherapy and radiosurgical boost: prognostic factors and long-term outcome. J Neurosurg 90:72-77 (Pubitemid 29024742)
24. Souhami L, Seiferheld W, Brachman D et al (2004) Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. Int J Radiat Oncol Biol Phys 60:853-860 (Pubitemid 39311766)
25. Stupp R, Mason WP, Bent MJ van den et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996 (Pubitemid 40349501)
26. Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459-466
27. Tsien C, Moughan J, Michalski JM et al (2009) Phase I three-dimensional conformal radiation dose escalation study in newly diagnosed glioblastoma: radiation therapy oncology group trial 98-03. Int J Radiat Oncol Biol Phys 73:699-708
28. Walker MD, Strike TA, Sheline GE (1979) Analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys 5:1725-1731 (Pubitemid 10187518)
29. Walker MD, Alexander E Jr, Hunt WE et al (1978) Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 49:333-343 (Pubitemid 9013313)
30. Weber DC, Casanova N, Zilli T et al (2009) Recurrence pattern after [(18)F]fluoroethyltyrosine-positron emission tomography-guided radiotherapy for high-grade glioma: a prospective study. Radiother Oncol 93:586-592
31. Wen PY, Macdonald DR, Reardon DA et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963-1972
32. Wick A, Felsberg J, Steinbach JP et al (2007) Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol 25:3357-3361 (Pubitemid 47325623)